FEED (FEED) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FEED (FEED) trades at $0.4018 with AI Score 16/100 (Grade F). ENvue Medical, Inc. focuses on developing noninvasive biological response-activating devices. Market cap: $3.74M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 31, 2026Analyst Coverage for FEED: FEED does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FEED against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FEED: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
FEED (FEED) Healthcare & Pipeline Overview
ENvue Medical, Inc. (FEED) specializes in noninvasive medical devices, including UroShield and PainShield, aimed at activating biological responses. Operating across the US, Europe, and other regions, the company faces challenges in a competitive medical device market while focusing on innovative solutions for targeted therapies.
What Is the Investment Thesis for FEED?
ENvue Medical, Inc. presents a speculative investment opportunity within the medical device sector. The company's focus on noninvasive biological response-activating devices, such as UroShield and PainShield, targets specific medical needs. Key value drivers include the potential for market adoption of UroShield in preventing CAUTIs and PainShield for localized pain relief. Growth catalysts involve expanding distribution networks and securing regulatory approvals in key markets. However, the company faces significant risks, including negative profit margins (-744.2%) and a negative gross margin (-12.4%). The company's small market capitalization ($0.00B) and high beta (1.59) indicate high volatility and sensitivity to market movements. Successful commercialization and revenue growth are critical for the company's long-term viability.
Based on FMP financials and quantitative analysis
FEED Key Highlights
Market Cap of $3.74M indicates a micro-cap company with high growth potential but also significant risk.
- Profit Margin of -744.2% reflects substantial losses and the need for improved cost management and revenue generation.
- Gross Margin of -12.4% suggests that the cost of goods sold exceeds revenue, indicating pricing or production inefficiencies.
- Beta of 1.59 indicates higher volatility compared to the market, making it a riskier investment.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than returning capital to shareholders.
Who Are FEED's Competitors?
FEED is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACIXF Acarix AB (publ) | $0.03 | +0.00% | $31.5M | 52 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.1M | 53 |
| EBRCZ EBR Systems, Inc. | $0.21 | -11.02% | $134M | 45 |
| SI SHOULDER INNOVATIONS, INC. | $23.26 | +10.08% | $482M | 30 |
| AVNBF Avon Technologies Plc | $22.49 | +0.00% | $662M | 38 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| BMXXY bioMérieux S.A. | $8.56 | +7.81% | $10.1B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FEED's Key Strengths?
Innovative noninvasive medical devices.
- Presence in multiple geographical markets.
- Focus on specific medical needs (CAUTI prevention, pain relief).
What Are FEED's Weaknesses?
Negative profit and gross margins.
- Small market capitalization.
- Limited financial resources.
What Could Drive FEED Stock Higher?
Potential FDA clearance for new indications of UroShield.
- Expansion of distribution networks in Europe.
- Clinical trials to demonstrate the efficacy of PainShield for chronic pain management.
What Are the Key Risks for FEED?
Financial-distress signal — its Altman Z-Score of -5.58 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-43.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from established medical device companies.
- Stringent regulatory requirements and potential delays in approvals.
- Negative profit margins and the need for improved financial performance.
What Are the Growth Opportunities for FEED?
- Expansion into New Therapeutic Areas: ENvue Medical has the opportunity to leverage its core technology to develop new applications in other therapeutic areas. For example, the company could explore the use of its noninvasive biological response-activating devices for wound healing or dermatology. The market for advanced wound care is projected to reach $22 billion by 2028, offering a significant growth opportunity. This expansion would require additional R&D investment and clinical trials, but could significantly broaden the company's market reach and revenue potential.
- Geographic Expansion: ENvue Medical currently operates in the United States, Europe, Australia, India, and Israel. Expanding into new geographic markets, such as Asia-Pacific and Latin America, could drive significant growth. The Asia-Pacific medical device market is expected to grow at a CAGR of 8% over the next five years, driven by increasing healthcare spending and aging populations. Successful geographic expansion would require adapting products to local regulatory requirements and establishing distribution partnerships.
- Strategic Partnerships: ENvue Medical could benefit from strategic partnerships with larger medical device companies or healthcare providers. These partnerships could provide access to new markets, distribution channels, and technological expertise. For example, partnering with a major hospital chain could facilitate the adoption of UroShield in preventing CAUTIs. Strategic alliances can accelerate market penetration and reduce the financial burden of commercialization.
- Regulatory Approvals: Securing regulatory approvals in key markets is crucial for ENvue Medical's growth. Obtaining FDA clearance for new products or indications would significantly enhance the company's credibility and market access in the United States. Similarly, obtaining CE marking in Europe would facilitate expansion in the European market. Navigating the regulatory landscape requires a dedicated team and a robust clinical data package.
- Product Innovation: Continuous product innovation is essential for maintaining a competitive edge in the medical device industry. ENvue Medical should invest in R&D to develop new and improved versions of its UroShield and PainShield products. This could involve incorporating new technologies, improving device performance, or expanding the range of applications. A strong focus on product innovation will help the company stay ahead of the competition and meet evolving customer needs.
What Threats Does FEED Face?
- Intense competition in the medical device industry.
- Stringent regulatory requirements.
- Risk of product obsolescence due to technological advancements.
What Are FEED's Competitive Advantages?
- Proprietary technology in noninvasive biological response-activating devices.
- Established presence in multiple geographical markets.
- Focus on specialized medical devices addressing specific needs.
What Does FEED Do?
NanoVibronix, Inc., now known as ENvue Medical, Inc., was founded in September 2003 by Harold Jacob and Jona Zumeris. The company is dedicated to the development and commercialization of noninvasive biological response-activating devices. Their core products, UroShield and PainShield, leverage proprietary technology to address specific medical needs without invasive procedures. UroShield is designed to prevent catheter-associated urinary tract infections (CAUTIs), while PainShield targets localized pain relief. ENvue Medical operates across several geographical segments, including the United States, Europe, Australia, India, and Israel, reflecting a global strategy. The company's headquarters are located in Tyler, TX, and it employs a team of 31 individuals. The company's evolution has been marked by a focus on innovation in noninvasive medical technology, aiming to improve patient outcomes and reduce healthcare costs. Their market position is characterized by a niche focus on specialized medical devices that offer alternatives to traditional treatments.
What Products and Services Does FEED Offer?
- Develops noninvasive biological response-activating devices.
- Offers UroShield for preventing catheter-associated urinary tract infections (CAUTIs).
- Provides PainShield for localized pain relief.
- Operates in the United States, Europe, Australia, India, and Israel.
- Focuses on improving patient outcomes through innovative medical technology.
- Aims to reduce healthcare costs by offering alternatives to traditional treatments.
How Does FEED Make Money?
- Develops and manufactures noninvasive medical devices.
- Sells products directly to healthcare providers and distributors.
- Generates revenue through product sales in various geographical markets.
What Industry Does FEED Operate In?
ENvue Medical, Inc. operates within the medical device industry, which is characterized by rapid technological advancements and stringent regulatory requirements. The market for noninvasive medical devices is growing, driven by patient preference for less invasive treatments and the increasing prevalence of chronic diseases. The competitive landscape includes both large, established medical device companies and smaller, innovative firms. ENvue Medical's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong distribution channels. The industry is subject to ongoing trends such as telemedicine, remote patient monitoring, and personalized medicine, which present both opportunities and challenges for ENvue Medical.
Who Are FEED's Key Customers?
- Hospitals and clinics seeking to reduce CAUTIs.
- Patients requiring localized pain relief.
- Healthcare providers looking for noninvasive treatment options.
Company Profile
FEED operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Tyler, US. The company is led by CEO Doron Robert Besser. FEED has traded publicly since 2025.
FEED Financial Trajectory
FEED (FEED) reported $653K in revenue for Q1 2026, reflecting 109.3% growth compared to the prior quarter. The company recorded a net loss of $3.8M, with diluted EPS of $-6877.67. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, FEED averaged $-1726.19 in diluted EPS.
How FEED Is Valued
FEED carries a market capitalization of $3.74M, placing it in the micro-cap category. Relative to its peer group, FEED's quantitative score of 16/100 is below the peer average of 44/100.
Key Financial Metrics
Return on equity for FEED stands at -43.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.7%, showing how much profit it generates from its asset base. A current ratio of 0.90 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
FEED's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.58 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project FEED revenue of about $229K for fiscal 2026, with EPS near $-1914.00.
FEED Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects. This could signal that those with the most knowledge about FEED believe it's undervalued.
- Community sentiment is leaning bullish, with many users expressing optimism about FEED's long-term growth potential. This positive buzz can attract more investors.
- FEED seems to be gaining traction in its market, with increasing mentions and positive reviews circulating online. This could translate to higher demand for their products or services.
- The overall market perception of FEED has improved recently, with more analysts and commentators highlighting its potential. This increased visibility can lead to greater investor interest.
Bear Case
- Some insiders have recently sold off shares, which might raise concerns about their confidence in the company's short-term performance. This could indicate they believe the stock is currently overvalued.
- A segment of the community expresses skepticism about FEED's ability to maintain its current growth rate, citing increased competition and potential regulatory hurdles. This negativity could deter potential investors.
- Market perception suggests FEED is facing challenges in scaling its operations and managing costs effectively. This could impact profitability and long-term sustainability.
- There are growing concerns within the community about FEED's competitive positioning, with some users suggesting that rival companies are gaining market share. This could lead to decreased revenue and profitability for FEED.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $653,000 | -$4M | -$6877.67 |
| Q4 2025 | $312,000 | -$13M | -$15.87 |
| Q3 2025 | $722,000 | $600,000 | -$0.91 |
| Q2 2025 | $494,000 | -$156,000 | -$10.30 |
Based on FMP financials and quantitative analysis
FEED Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Aug 12, 2026
-
ENvue Medical Appoints Zeev Rotstein Board Chair, Succeeding David Johnson
benzinga · Jul 15, 2026
-
ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
globenewswire.com · Jul 15, 2026
-
Envue Medical Names Zeev Rotstein As Chairman Of The Board
benzinga · Jul 14, 2026
FEED Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FEED.
Price Targets
Wall Street price target analysis for FEED.
FEED MoonshotScore
What does this score mean?
The MoonshotScore rates FEED 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session
ENvue Medical Appoints Zeev Rotstein Board Chair, Succeeding David Johnson
ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
Envue Medical Names Zeev Rotstein As Chairman Of The Board
Leadership: Doron Robert Besser
CEO
Doron Robert Besser serves as the CEO of ENvue Medical, Inc. His background includes experience in managing and scaling healthcare companies, with a focus on medical device commercialization. He has a proven track record in strategic planning, business development, and financial management. Besser's expertise lies in guiding companies through critical growth phases and navigating the complexities of the healthcare industry. His leadership is focused on driving innovation and expanding market reach for ENvue Medical's products.
Track Record: Under Doron Robert Besser's leadership, ENvue Medical has focused on expanding its product offerings and market presence. Key milestones include securing strategic partnerships and navigating regulatory approvals for UroShield and PainShield. Besser has emphasized the importance of innovation and customer satisfaction, aiming to establish ENvue Medical as a leader in noninvasive medical technology.
Common Questions About FEED (Healthcare)
What does the AI Score mean for FEED?
FEED holds an AI Score of 16/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. ENvue Medical, Inc. focuses on developing noninvasive biological response-activating devices. Their product line includes UroShield and PainShield, targeting markets in the United States, Europe …
What does ENvue Medical, Inc. do?
ENvue Medical, Inc. specializes in the development and commercialization of noninvasive medical devices designed to activate biological responses. Their primary products include UroShield, aimed at preventing catheter-associated urinary tract infections (CAUTIs), and PainShield, which provides localized pain relief.
What do analysts say about FEED stock?
Given ENvue Medical, Inc.'s micro-cap status and negative profitability, analyst coverage may be limited. However, potential investors should focus on key valuation metrics such as revenue growth, gross margin improvement, and progress towards profitability. The company's success hinges on the adoption of its UroShield and PainShield products, regulatory approvals, and strategic partnerships.
What are the main risks for FEED?
ENvue Medical, Inc. faces several significant risks. The company's negative profit and gross margins indicate financial instability and the need for improved cost management and revenue generation. Competition from larger, more established medical device companies poses a threat to market share. Regulatory hurdles and potential delays in obtaining approvals for new products or indications could impede growth.
What are the key factors to evaluate for FEED?
FEED holds an AI score of 16/100 (low). ENvue Medical, Inc. presents a speculative investment opportunity within the medical device sector. Not financial advice.
How frequently does FEED data refresh on this page?
FEED's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FEED's recent stock price performance?
FEED moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative noninvasive medical devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FEED overvalued or undervalued right now?
FEED is loss-making, so its trailing P/E is negative (-0.6x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FEED before investing?
Before investing in FEED, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Financial data is limited and may not reflect the most current performance.